By Mill Chart
Last update: May 3, 2024
Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is suited for quality investing. Investors should of course do their own research, but we spotted NEUROCRINE BIOSCIENCES INC showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.
ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.
Overall NBIX gets a fundamental rating of 8 out of 10. We evaluated NBIX against 588 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues. NBIX is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make NBIX a good candidate for value and growth and quality investing.
Check the latest full fundamental report of NBIX for a complete fundamental analysis.
Our Caviar Cruise screen will find you more ideas suited for quality investing.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (5/17/2024, 7:15:36 PM)
After market: 142.29 0 (0%)142.29
+0.38 (+0.27%)
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present CAHtalyst™ Adult Phase 3 clinical study baseline...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety,...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD...
The market rally appears to be picking up steam.
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for...